Sign In
Buy ADMA
ADMA Biologics Earnings Calls
| Release date | May 06, 2026 |
| EPS estimate | $0.193 |
| EPS actual | $0.190 |
| EPS Surprise | -1.71% |
| Revenue estimate | 139.976M |
| Revenue actual | 114.493M |
| Revenue Surprise | -18.20% |
| Release date | Feb 25, 2026 |
| EPS estimate | $0.185 |
| EPS actual | $0.200 |
| EPS Surprise | 8.11% |
| Revenue estimate | 139.6M |
| Revenue actual | 139.163M |
| Revenue Surprise | -0.313% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.160 |
| EPS actual | $0.160 |
| Revenue estimate | 139.8M |
| Revenue actual | 134.224M |
| Revenue Surprise | -3.99% |
| Release date | Aug 06, 2025 |
| EPS estimate | $0.140 |
| EPS actual | $0.150 |
| EPS Surprise | 7.14% |
| Revenue estimate | 130.3M |
| Revenue actual | 121.984M |
| Revenue Surprise | -6.38% |
Last 4 Quarters for ADMA Biologics
Below you can see how ADMA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $18.54 |
| EPS estimate | $0.140 |
| EPS actual | $0.150 |
| EPS surprise | 7.14% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $18.70 |
| Aug 01, 2025 | $19.33 |
| Aug 04, 2025 | $19.91 |
| Aug 05, 2025 | $18.96 |
| Aug 06, 2025 | $18.54 |
| Aug 07, 2025 | $16.75 |
| Aug 08, 2025 | $16.52 |
| Aug 11, 2025 | $16.38 |
| Aug 12, 2025 | $16.76 |
| 4 days before | -0.86% |
| 4 days after | -9.60% |
| On release day | -9.65% |
| Change in period | -10.37% |
| Release date | Nov 05, 2025 |
| Price on release | $15.37 |
| EPS estimate | $0.160 |
| EPS actual | $0.160 |
| Date | Price |
|---|---|
| Oct 30, 2025 | $15.27 |
| Oct 31, 2025 | $15.48 |
| Nov 03, 2025 | $15.37 |
| Nov 04, 2025 | $14.63 |
| Nov 05, 2025 | $15.37 |
| Nov 06, 2025 | $14.03 |
| Nov 07, 2025 | $14.52 |
| Nov 10, 2025 | $14.71 |
| Nov 11, 2025 | $16.03 |
| 4 days before | 0.655% |
| 4 days after | 4.29% |
| On release day | -8.72% |
| Change in period | 4.98% |
| Release date | Feb 25, 2026 |
| Price on release | $15.68 |
| EPS estimate | $0.185 |
| EPS actual | $0.200 |
| EPS surprise | 8.11% |
| Date | Price |
|---|---|
| Feb 19, 2026 | $16.32 |
| Feb 20, 2026 | $16.10 |
| Feb 23, 2026 | $16.29 |
| Feb 24, 2026 | $15.52 |
| Feb 25, 2026 | $15.68 |
| Feb 26, 2026 | $15.18 |
| Feb 27, 2026 | $15.57 |
| Mar 02, 2026 | $16.58 |
| Mar 03, 2026 | $16.38 |
| 4 days before | -3.92% |
| 4 days after | 4.46% |
| On release day | -3.19% |
| Change in period | 0.368% |
| Release date | May 06, 2026 |
| Price on release | $10.08 |
| EPS estimate | $0.193 |
| EPS actual | $0.190 |
| EPS surprise | -1.71% |
| Date | Price |
|---|---|
| Apr 30, 2026 | $10.25 |
| May 01, 2026 | $10.52 |
| May 04, 2026 | $10.31 |
| May 05, 2026 | $10.25 |
| May 06, 2026 | $10.08 |
| May 07, 2026 | $8.47 |
| May 08, 2026 | $8.17 |
| May 11, 2026 | $7.88 |
| May 12, 2026 | $8.41 |
| 4 days before | -1.66% |
| 4 days after | -16.57% |
| On release day | -15.97% |
| Change in period | -17.95% |
ADMA Biologics Earnings Call Transcript Summary of Q1 2026
ADMA Biologics reported a solid first quarter 2026 with flat total revenue ($114.5M) but strong underlying profitability and cash generation. ASCENIV grew ~28% year-over-year and showed record utilization, new patient starts and prescriber adoption, while BIVIGAM revenue declined ~54% due to heightened competitive discounting and distributor inventory/order variability. The company completed the sale of three plasma centers, added a third-party plasma supplier, and increased margin efficiency (corporate gross margin expanded to 71%), generating approximately $58M of operating cash flow in the quarter. Management characterized current market conditions as a transient industry-wide dislocation caused by new entrants, temporary oversupply of plasma/finished IG and aggressive pricing, and said ASCENIV demand appears resilient and is likely the foundation for future growth. ADMA reiterated confidence in its SG-001 pipeline (pre-IND work and upcoming preclinical data presentation) and emphasized a disciplined pricing strategy, margin focus and capital allocation (including opportunistic share repurchases). Updated 2026 outlook: total revenue $530M–$560M, adjusted EBITDA $265M–$300M, adjusted net income $170M–$200M; long-term guidance withdrawn due to ongoing competitive uncertainty. Management expects DSOs to normalize to ~90–105 days in H2 2026 as ordering patterns and distribution mix (including McKesson ramp) stabilize.
